Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

STATUS

Recruiting
participants needed

40
sponsor

ESSA Pharmaceuticals

Send

Updated on 19 February 2024

See if I qualify

metastasis

progressive disease

bone scan

metastatic castration-resistant prostate cancer

soft tissue disease

bone lesion

castration-resistant prostate cancer

diphosphonates

Summary

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386.

Since this is the first study of EPI-7386 in humans, there is no information about how it affects people or what dose should be used. Therefore, the main purpose of this study is to assess the safety (side effects) of EPI-7386 and to find a dose that can be given without unacceptable side effects.

There are other important things that will be evaluated during the study:

How the amount of EPI-7386 in the blood changes over time.
The effect of EPI-7386 on prostate cancer.
The effect of EPI-7386 on certain substances in the body.
The possibility that EPI-7386 can interact with other drugs.

Details

Condition	Malignant neoplasm of prostate, Prostatic disorder
Age	18years - 100years
Treatment	EPI-7386
Clinical Study Identifier	NCT04421222
Sponsor	ESSA Pharmaceuticals
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Male 18 years of age or older
	Histologically, pathologically, or cytologically confirmed prostate cancer without small cell features
	Evidence of castration-resistant prostate cancer (CRPC)
	Presence of metastatic disease at study entry documented by 1 or more bone lesions on bone scan or by soft tissue disease observed by CT/MRI
	No further treatment options available known to confer clinical benefit in this disease setting from the perspective of the treating physician
	Evidence of progressive disease defined as 1 or more Prostate Cancer Working Group 3 (PCWG3) criteria
	The patient must have recovered from toxicities related to any prior treatments
	Castrate at screening
	Patients receiving bisphosphonates or other approved bone-targeting therapy must be on a stable dose for at least 4 weeks prior to the start of study drug
	Demonstrate adequate organ function
	Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1
Exclusion Criteria
	Biologic anti-cancer therapy or a cytotoxic chemotherapy within 4 weeks prior to the start of study drug
	Use of hormonal agents with anti-tumor activity against prostate cancer within 4 weeks prior to the start of study drug
	Intervention with any chemotherapy, investigational agents, or other anti-cancer drugs within 14 days or 5 half-lives, whichever is longer, of the first dose of study drug
	Use of radium-223 dichloride or other radioligand/radiopharmaceutical within 28 days prior to the start of study drug
	Received limited-field palliative bone radiotherapy >5 fractions and/or any radiotherapy within 2 weeks prior to the start of study drug
	Received a blood transfusion within 28 days of screening
	Known intra-cerebral disease or brain metastasis unless adequately treated and stable for the last 4 weeks before enrollment
	Spinal cord compression
	Diagnosis of another invasive malignancy within the previous 3 years other than curatively treated non-melanomatous skin cancer or superficial urothelial carcinoma
	Gastrointestinal disorder affecting absorption
	Significant cardiovascular disease
	Concurrent disease or any clinically significant abnormality
	Use of compounds known to be strong inducers and strong inhibitors of CYP3A and CYP2C8 within 14 days of the first dose of study drug
	Use of narrow therapeutic index sensitive CYP2C8 or sensitive substrates for CYP3A and CYP2B6

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

metastasis

progressive disease

bone scan

metastatic castration-resistant prostate cancer

soft tissue disease

bone lesion

castration-resistant prostate cancer

diphosphonates

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer